Alnylam advances Alzheimer's drug trials, reports mivelsiran safety data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease
July 15, 2026 3:30 AM EDTInitiates Global Phase 2 APPlauDS Study of Mivelsiran in Down SyndromeAssociated Alzheimers Disease (DS-AD)
Announces Completion of Enrollment in the Phase 2 cAPPricorn-1 Study of Mivelsiran in Cerebral Amyloid Angiopathy (CAA)
Presents Updated Phase 1 Data on Mivelsiran in Early Onset Alzheimers Disease (EOAD) Showing Low Incidence of Amyloid-Related Imaging Abnormalities (ARIA)
Shares Preclinical Data and Design of Ongoing Phase 1 Study of Tau-Targeting ALN5288 in Alzheimers Patients
CAMBRIDGE, Mass.--(BUSINESS... More
